Search research articles
Contact Us
Filters
Showing results (41-50 of 98) with videos related to
Page
of 10
Sort By:
Cancers
|
January 11, 2025
Clinically Significant <i>BRCA1</i> and <i>BRCA2</i> Germline Variants in Breast Cancer-A Single-Center Experience
Răzvan Mihail Pleșea, Anca-Lelia Riza, Ana Maria Ahmet, et al.
International Journal of Molecular Sciences
|
April 17, 2025
GAS5 rs145204276 Ins/Del Polymorphism Is Associated with CRC Susceptibility in a Romanian Population
Cecil Sorin Mirea, Michael Schenker, Bianca Petre-Mandache, et al.
JTO Clinical and Research Reports
|
October 13, 2025
Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC
Sun Min Lim, Ana Laura Ortega Granados, Gustavo Dix Junqueira Pinto, et al.
Therapeutic Advances in Medical Oncology
|
May 12, 2025
Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study
Glenwood Goss, Tudor Ciuleanu, Rodryg Ramlau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 30, 2024
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy
Maximilian Hochmair, Michael Schenker, Manuel Cobo Dols, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 10, 2026
Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L)
Suresh S Ramalingam, Vamsidhar Velcheti, Mehmet Altan, et al.
Nature Communications
|
November 11, 2023
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
Sun Min Lim, Solange Peters, Ana Laura Ortega Granados, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
January 28, 2024
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial
Yoon-Koo Kang, Min-Hee Ryu, Maria Di Bartolomeo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 9, 2024
The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC
Jhanelle E Gray, Michael Schenker, Mehmet Ali Nahit Şendur, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 14, 2019
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Martin Reck, Michael Schenker, Ki Hyeong Lee, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 98) with videos related to
Sort By:
Page
of 10
Cancers
|
January 11, 2025
Clinically Significant <i>BRCA1</i> and <i>BRCA2</i> Germline Variants in Breast Cancer-A Single-Center Experience
Răzvan Mihail Pleșea, Anca-Lelia Riza, Ana Maria Ahmet, et al.
International Journal of Molecular Sciences
|
April 17, 2025
GAS5 rs145204276 Ins/Del Polymorphism Is Associated with CRC Susceptibility in a Romanian Population
Cecil Sorin Mirea, Michael Schenker, Bianca Petre-Mandache, et al.
JTO Clinical and Research Reports
|
October 13, 2025
Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC
Sun Min Lim, Ana Laura Ortega Granados, Gustavo Dix Junqueira Pinto, et al.
Therapeutic Advances in Medical Oncology
|
May 12, 2025
Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study
Glenwood Goss, Tudor Ciuleanu, Rodryg Ramlau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 30, 2024
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy
Maximilian Hochmair, Michael Schenker, Manuel Cobo Dols, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 10, 2026
Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L)
Suresh S Ramalingam, Vamsidhar Velcheti, Mehmet Altan, et al.
Nature Communications
|
November 11, 2023
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
Sun Min Lim, Solange Peters, Ana Laura Ortega Granados, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
January 28, 2024
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial
Yoon-Koo Kang, Min-Hee Ryu, Maria Di Bartolomeo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 9, 2024
The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC
Jhanelle E Gray, Michael Schenker, Mehmet Ali Nahit Şendur, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 14, 2019
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Martin Reck, Michael Schenker, Ki Hyeong Lee, et al.
Page
of 10